OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Trends in PCSK9 inhibitor utilization in the United States, Europe, and other countries: An analysis of international sales data
Joseph E. Blais, Yue Wei, Martín Knapp, et al.
American Heart Journal (2022) Vol. 248, pp. 13-20
Open Access | Times Cited: 8
Joseph E. Blais, Yue Wei, Martín Knapp, et al.
American Heart Journal (2022) Vol. 248, pp. 13-20
Open Access | Times Cited: 8
Showing 8 citing articles:
Real‐World Effectiveness of PCSK9 Inhibitors in Reducing LDL‐C in Patients With Familial Hypercholesterolemia in Italy: A Retrospective Cohort Study Based on the AIFA Monitoring Registries
Marcello Arca, Simone Celant, Pier Paolo Olimpieri, et al.
Journal of the American Heart Association (2023) Vol. 12, Iss. 21
Open Access | Times Cited: 16
Marcello Arca, Simone Celant, Pier Paolo Olimpieri, et al.
Journal of the American Heart Association (2023) Vol. 12, Iss. 21
Open Access | Times Cited: 16
The Hurdle of Access to Emerging Therapies and Potential Solutions in the Management of Dyslipidemias
Brett S. Mansfield, Farzahna Mohamed, Miriam Larouche, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 14, pp. 4160-4160
Open Access | Times Cited: 6
Brett S. Mansfield, Farzahna Mohamed, Miriam Larouche, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 14, pp. 4160-4160
Open Access | Times Cited: 6
Current and future role of PCSK9 inhibitors in ASCVD prevention
Antonio Greco, Davide Capodanno
Future Cardiology (2025), pp. 1-3
Closed Access
Antonio Greco, Davide Capodanno
Future Cardiology (2025), pp. 1-3
Closed Access
PCSK9 Inhibitors in the Management of Cardiovascular Risk: A Practical Guidance
Xiaoming Jia, Mahmoud Al Rifai, Anum Saeed, et al.
Vascular Health and Risk Management (2022) Vol. Volume 18, pp. 555-566
Open Access | Times Cited: 20
Xiaoming Jia, Mahmoud Al Rifai, Anum Saeed, et al.
Vascular Health and Risk Management (2022) Vol. Volume 18, pp. 555-566
Open Access | Times Cited: 20
Mechanisms of unusual response to lipid-lowering therapy: PCSK9 inhibition
Mingqi Ouyang, Chenyu Li, Die Hu, et al.
Clinica Chimica Acta (2022) Vol. 538, pp. 113-123
Closed Access | Times Cited: 4
Mingqi Ouyang, Chenyu Li, Die Hu, et al.
Clinica Chimica Acta (2022) Vol. 538, pp. 113-123
Closed Access | Times Cited: 4
Real-World safety and effectiveness of evolocumab in primary hypercholesterolemia and mixed dyslipidemia in Saudi Arabia
Abdulaali R. Almutairi, Walaa A Alshahrani, Ghaida K Alhathlol, et al.
Saudi Pharmaceutical Journal (2024) Vol. 32, Iss. 12, pp. 102203-102203
Open Access
Abdulaali R. Almutairi, Walaa A Alshahrani, Ghaida K Alhathlol, et al.
Saudi Pharmaceutical Journal (2024) Vol. 32, Iss. 12, pp. 102203-102203
Open Access
Challenges with PCSK9 Inhibitors Use in Asia Given Real-World Data Implications
Kiyoko Uno-Eder
Journal of Atherosclerosis and Thrombosis (2023) Vol. 30, Iss. 9, pp. 1106-1107
Open Access | Times Cited: 1
Kiyoko Uno-Eder
Journal of Atherosclerosis and Thrombosis (2023) Vol. 30, Iss. 9, pp. 1106-1107
Open Access | Times Cited: 1
Review on PCSK9: A Pertinent Therapeutic Target in Cardiovascular Disease
Sonia Singh, Manas Kumar Jha
Current Bioactive Compounds (2023) Vol. 20, Iss. 1
Closed Access
Sonia Singh, Manas Kumar Jha
Current Bioactive Compounds (2023) Vol. 20, Iss. 1
Closed Access
